


Curriculum Vitae

Name	Changhoon Yoo	
Current Position & Affiliation	Associate Professor, Department of Oncology, Asan Medical Center, Seoul, Korea	
Country	Republic of Korea	

Educational Background

2006 MD University of Ulsan College of Medicine

2019 PhD University of Ulsan College of Medicine

Professional Experience

2007-2011: Resident, Department of Internal Medicine, Asan Medical Center

2014-2016: Clinical Fellow, Department of Oncology, Asan Medical Center

2016-2020: Assistant Professor, Department of Oncology, Asan Medical Center

2020-present: Associate Professor, Department of Oncology, Asan Medical Center

Professional Organizations

Member, Korean Society of Medical Oncology

Member, Korean Cancer Association

Member, Korean Liver Cancer Association

Member, American Society of Clinical Oncology

Member, European Society of Medical Oncology

Main Scientific Publications

1. Kim, E. J. and Yoo, C *et al.* Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. *Liver Int* (2021) doi:10.1111/liv.14813.

2. Kim, H. and Yoo, C *et al.* Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. *Liver International* **40**, liv.14573-9 (2020).
 3. Yoo, C. *et al.* Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. *Liver International* liv.14496-9 (2020) doi:10.1111/liv.14496.
 4. Yoo, C. *et al.* Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. *Cancer Research and Treatment* **51**, 510–518 (2019).
 5. Cheon, J. and Yoo C, *et al.* Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. *Liver Cancer* 1–12 (2020) doi:10.1159/000508901.
 6. Yoo, C. *et al.* Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. *Liver Cancer* 1–8 (2021) doi:10.1159/000512781.
-